Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: A case-control study

Neurogastroenterology and Motility

Volumn 24, Issue 9, 2012, Pages

  Tursi, A ^a   Elisei, W ^b   Brandimarte, G ^c   Giorgetti, G M ^d   Inchingolo, C D ^e   Nenna, R ^e   Picchio, M ^f   Giorgio, F ^g   Ierardi, E ^g  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c Cristo Re Hospital   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

^e Lorenzo Bonomo Hospital   (Italy)

^f Paolo Colombo Hospital   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Basic fibroblastic growth factor; Diverticular disease; Diverticulitis; Syndecan 1; Tumoral necrosis factor

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MESALAZINE; METRONIDAZOLE; RIFAXIMIN; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE UNCOMPLICATED DIVERTICULITIS; ADULT; AGED; ARTICLE; ASYMPTOMATIC DIVERTICULOSIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLITIS; COLON DIVERTICULOSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEGMENTAL COLITIS ASSOCIATED WITH DIVERTICULOSIS; SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLITIS; COLITIS, ULCERATIVE; COLON; DIVERTICULITIS, COLONIC; DIVERTICULOSIS, COLONIC; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; MALE; MESALAMINE; METRONIDAZOLE; MIDDLE AGED; RIFAMYCINS; SYNDECAN-1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865408875     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01946.x     Document Type: Article

References (50)

1. Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009; 30: 532-46.
2. Tursi A. New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opin Pharmacoter 2007; 8: 299-307.
3. Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
4. Braegger CP, Nicholls S, Murch SH. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
5. Reinecker HC, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1b by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
6. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-82.
7. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA. Analysis of Th1 and Th2 cytokines expressing CD4 + and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27: 1128-35.
8. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-9.
9. Hassan C, Ierardi E, Burattini O et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 39: 811-7.
10. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 1993; 30: 1443-53.
11. Fiorino G, Szabò H, Walter F, Malesci A, Peyrin-Biroulet L, Danese S. Adalimumab in Crohn's disease: tips and tricks after 5years of clinical experience. Curr Med Chem 2011; 18: 1230-8.
12. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
13. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
14. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med 2004; 350: 876-85.
15. Saunders S, Jalkanen M, O'Farrell S, Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 1989; 108: 1547-56.
16. Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Expression of Syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 1999; 44: 2508-15.
17. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 1994; 5: 353-77.
18. Day R, Forbes A. Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-4.
19. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 44-60.
20. Lawrance IC, Maxwell L. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 226-36.
21. Mimura T, Bateman AC, Lee RL et al. Up-regulation of collagen and tissue inhibitors of matrix metalloproteinase in colonic diverticular disease. Dis Colon Rectum 2004; 47: 371-8.
22. Okamura K, Sato Y, Matsuda T et al. Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells. J Biol Chem 1991; 266: 19162-5.
23. Yoshida S, Shono T, Izumi H et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015-23.
24. Köhler L, Sauerland S, Neugebauer E for the Scientific Committee of the European Association for Endoscopic Surgery (E.A.E.S.). Diagnosis and treatment of diverticular disease. Results of a Consensus Development Conference. Surg Endosc 1999;13: 430-6.
25. Pereira JM, Sirlin CB, Pinto PS, Jeffrey RB, Stella DL, Casola G. Disproportionate fat stranding: a helpful ct sign in patients with acute abdominal pain. RadioGraphics 2004; 24: 703-15.
26. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Maiorano M, Aiello F. The clinical picture of uncomplicated versus complicated diverticulitis of the colon. Dig Dis Sci 2008; 53: 2474-9.
27. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49-55.
28. Schusselé Filliettaz S, Gonvers JJ, Peytremann-Bridevaux I et al. EPAGE II Study Group. Appropriateness of colonoscopy in Europe (EPAGE II). Functional bowel disorders: pain, constipation and bloating. Endoscopy 2009;41:234-9.
29. Schusselé Filliettaz S, Juillerat P, Burnand B et al. EPAGE II Study Group. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy 2009; 41: 218-26.
30. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131: 1981-2002.
31. Gasbarrini A, Corazza GR, Gasbarrini G et al., 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther 2009; 29(Suppl. 1): 1-49.
32. Escobedo AA, Almirall P, Robertson LJ et al. Giardiasis: the ever-present hreat of a neglected disease. Infect Disord Drug Targets 2010; 10: 329-48.
33. Tursi A, Elisei W, Brandimarte G et al. The endoscopic spectrum of segmental colitis associated with diverticulosis. Colorectal Dis 2010; 12: 464-70.
34. Rizzello F, Gionchetti P, D'Arienzo A et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 1109-16.
35. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): v70-7.
36. Ierardi E, Giorgio F, Rosania R et al. Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples: a comparison between immunohistochemistry and real time polymerase chain reaction. Scand J Gastroenterol 2010; 45: 1007-8.
37. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-93.
38. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
39. Tursi A, Brandimarte G, Elisei W et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008; 42: 699-703.
40. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-67.
41. Tursi A. Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity? Dig Dis Sci 2011; 56: 27-34.
42. Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci 2011; 56: 3112-21.
43. Meijer MJ, Mieremet-Ooms MA, van derZonAM et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39: 733-9.
44. Morson BC. The muscle abnormality in diverticular disease of the colon. Proc R Soc Med 1963; 56: 798-803.
45. Baert FJ, D'Haens GR, Peeters M et al. Tumour necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-8.
46. Ierardi E, Giorgio F, Zotti M et al. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis. J Clin Pathol 2011; 64: 968-72.
47. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000; 279: G653-9.
48. Rieder F, Brenmoehl J, Leeb S, Schölmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007; 56: 130-9.
49. Gao Q, Hogezand RA, Lamers CB, Verspaget HW. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Aliment Pharmacol Ther 2004; 20: 585-92.
50. Halme L, Lappalainen M, Fodstad H et al. CARD15/NOD2 gene variants are associated with familiarly occurring and complicated forms of Crohn's disease. Gut 2003; 52: 558-62.